Spectral Medical Inc.

43 articles with Spectral Medical Inc.

• Dialco Medical Inc. Engages CROMSOURCE as Contract Research Organization Partner for DIMI IDE Trial

  6/7/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Dialco has engaged CROMSOURCE, a full-service Contract Research Organization (“CRO”), for its upcoming DIMI IDE usability clinical trial.

• Spectral Announces First Quarter Results and Provides Corporate Update

  5/14/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced its financial results for the first quarter ended March 31, 2021, and provided a corporate update.

• Spectral Medical’s Wholly-Owned Subsidiary Dialco Medical Announces DIMI Usability Trial Posted on the ClinicalTrials.gov Website

  5/5/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that the DIMI usability trial, run by its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco''), is registered and posted on the ClinicalTrials.gov website under the identifier of NCT04868643.

• Spectral Medical Announces Exercise of Warrants for Gross Proceeds of Approximately $3.0 Million

  4/15/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”)

• Spectral Medical’s Dialco Medical Announces 20 Year Exclusive License Agreement for DIMI Hemodialysis System in the United States and Canada

  4/8/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”) has entered into an expanded, long-term licensing agreement with Infomed SA (“Infomed”) for the DIMI hemodialysis system, extending Dialco’s exclusive rights in the United States and Canada through 2041.

• Spectral Medical’s Wholly-Owned Subsidiary Dialco Medical Announces Receipt of Health Canada License for DIMI

  3/31/2021

  Spectral Medical Inc., announced that its wholly-owned subsidiary, Dialco Medical Inc. has obtained its Health Canada license for the DIMI RRT system.

• Spectral Announces Fourth Quarter and Fiscal 2020 Results and Corporate Update

  3/26/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the fourth quarter and for the year ended December 31, 2020 and provided a corporate update.

• Spectral Medical Announces the Appointment of Chris Seto to CEO

  3/8/2021

  Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial

• Spectral Medical Engages Crescendo Communications to Provide Investor Relations Services in the United States

  3/4/2021

  Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc., announces that it has retained Crescendo Communications, LLC as its investor relations firm to help broaden awareness of the Company in the US financial markets.

• Spectral Medical to participate at the upcoming H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”),

• Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical has been Granted FDA IDE Authorization to Conduct a Trial of DIMI for Home Hemodialysis Use

  2/23/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”) , has been granted Investigational Device Exemption (IDE) authorization by the United States Food and Drug Administration (FDA) to conduct a usability trial to demonstrate the safety and efficacy of DIMI for performing hemodialysis in the home environment.

• Spectral Medical Appoints Dr. John Kellum as Chief Medical OfficerA World Authority in Blood Purification and Renal Replacement Therapy

  2/1/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. (“Dialco”), today announced the appointment of Dr. John Kellum, MD, MCCM as Chief Medical Officer.

• Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference

  1/11/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will be presenting at the H.C. Wainwright Virtual BioConnect Conference,

• Spectral Medical to Present at the SNN Network Canada Virtual Event on January 7, 2021

  1/6/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will be presenting at the SNN Network Canada Virtual Event on Thursday, January 7, 2021 at 4:00 p.m. E

• Spectral Medical to Host Virtual Investor Day on December 4, 2020

  11/27/2020

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. ( “ Dialco ” ), today announced the details for the Company’s upcoming Virtual Investor Day, scheduled to be held on Friday, December 4, 2

• Spectral Medical Announces that its wholly owned subsidiary Dialco Medical has received MDSAP certification

  11/24/2020

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market, today announced that its wholly owned subsidiary, Dialco Medical Inc. ( “ Dialco ” ) received its Med

• Spectral Medical Announces Report on Clinical Implementation of SAMI Amid COVID-19 Published in the Journal of Blood Purification

  11/11/2020

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market, today announced that a paper reporting on the deployment and use of its SAMI unit during the COVID-19 pandemic has been published in the Journal of Blood Purification.

• Spectral Announces Third Quarter 2020 Results

  11/11/2020

  Dialco’s DIMI receives FDA 510(k) clearance for use in hospital and clinical settings – a significant step in the full regulatory development of DIMI

• Spectral and Dialco Sponsored Symposiums at the 38th Vicenza Course on AKI and CRRT

  11/3/2020

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical In. (“Dialco”) , are pleased to announce the following sponsored symposiums at the virtual 38 th Vicenza Course on AKI and CRRT from Monday, November 2nd, 2020 to Friday, November 6th, 2020: Meet the Expert: Is Endotoxemia Relevant in COVID-19? Moderator: Kianoush Kashani, Guest Speakers: Sandeep Mallipattu, and David Yamane Novemb

• Spectral to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

  9/8/2020

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , announced today that Dr. Paul Walker, Spectral’s Chief Executive Officer and Chris Seto, Spectral’s Chief Operating and Chief Financial Officer will be presenting virtually at the H.C. Wainwright & Co.  22 nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 5:00 p.m. ET. About Spectral Spectral is a Phase III company seeking U.S. FDA approval for its un